| Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
| 2017-06-26 |
Nabriva Therapeutics (Ireland) |
board of directors |
|
nomination |
Infectious diseases |
Nomination |
| 2017-06-21 |
Eli Lilly (USA - IN) |
Lilly Biotechnology Center in San Diego |
|
opening of new premises |
|
Opening of new premises |
| 2017-06-21 |
Sarepta Therapeutics (USA - MA) Genethon (France) |
micro-dystrophin gene therapy |
Duchenne muscular dystrophy (DMD) |
R&D - research - development |
Rare diseases - Genetic diseases - Hematological diseases |
Research agreement |
| 2017-06-21 |
InflaRx (Germany) |
chief medical officer |
|
nomination |
Inflammatory diseases |
Nomination |
| 2017-06-20 |
Argen-X (Belgium - The Netherlands) Leo Pharma (Denmark) |
antibody-based solutions (ARGX-112) |
chronic inflammation underlying skin conditions. |
licensing - development |
Dermatological diseases - Inflammatory diseases |
Milestone |
| 2017-06-20 |
Cell Therapy Catapult (UK) Cell Medica (UK) |
WT1 T cell receptor (TCR) cell therapy, cell therapy manufacturing operations |
acute myeloid leukaemia, myelodysplastic syndrome |
collaboration |
Cancer - Oncology |
Collaboration agreement |
| 2017-06-19 |
Txcell (France) Lentigen Technology (USA - MD), a wholly owned subsidiary of Miltenyi Biotech (Germany) |
HLA-A2 CAR lentiviral vector |
prevention of chronic rejection after organ transplantation |
- services contract - manufacturing - production
|
Transplantation |
Services contract |
| 2017-06-19 |
Medivir (Sweden) |
|
|
nomination |
Cancer - Oncology - Infectious diseases |
Nomination |
| 2017-06-19 |
Takeda Pharmaceutical (Japan) Heidelberg Pharma (Germany) |
Antibody Targeted Amanitin Conjugates (ATACs) |
|
research |
undisclosed |
Research agreement |
| 2017-06-16 |
Recordati (Italy) Mimetech (Italy) |
low molecular weight peptidomimetic of human nerve growth factor (NGF) ((1S,4R,5R,7S)-3,4-dibenzyl-2-oxo-6,8-dioxa-3-azabyciclo[3.2.1]octane-7-carboxylic acid-L-lysine) |
neurotrophic keratitis |
licensing - development - commercialisation |
Rare diseases - Ophtalmological diseases |
Licensing agreement |
| 2017-06-15 |
CitoxLab (France) KaLy-Cell (France) |
in vitro and ex vivo testing for hepatotoxicity and metabolism |
|
collaboration |
Technology - Services |
Collaboration agreement |
| 2017-06-15 |
TiGenix (Belgium) Crohn's and Colitis Foundation's President's Corporate Circle (USA - NY) European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) (Belgium) |
|
Crohn's disease, ulcerative colitis |
collaboration |
Autoimmune diseases - Inflammatory diseases - Digestive diseases |
Collaboration agreement |
| 2017-06-15 |
VBL Therapeutics (Israel) |
chief operating officer |
|
nomination |
Cancer - Oncology |
Nomination |
| 2017-06-14 |
Basilea Pharmaceutica (Switzerland) Pfizer (USA - NY) |
Cresemba® |
invasive aspergillosis and mucormycosis |
commercialisation |
Infectious diseases |
Commercialisation agreement |
| 2017-06-13 |
Ablynx (Belgium) |
|
|
nomination |
|
Nomination |
| 2017-06-13 |
Audentes Therapeutics (USA - CA) |
|
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
| 2017-06-12 |
Zymeworks (Canada) Eli Lilly (USA - IN) |
bispecific therapeutic candidates toward Lilly’s therapeutic targets using Azymetric™ platform |
undisclosed |
R&D - licensing |
Cancer - Oncology |
Milestone |
| 2017-06-12 |
Zealand Pharma (Denmark) Helsinn Healthcare (Switzerland) |
elsiglutide |
chemotherapy-induced diarrhea |
termination of an agreement |
Cancer - Oncology |
Termination of an agreement |
| 2017-06-12 |
Tiziana Life Sciences (UK) |
|
|
nomination |
Autoimmune diseases - Cancer - Oncology |
Nomination |
| 2017-06-12 |
GlycoMimetics (USA - Md) |
|
|
nomination |
|
Nomination |
